The serum bactericidal test.

Area of Science:

• Microbiology
• Clinical Medicine
• Pharmacology

Background:

• The serum bactericidal test (SBT) is a long-standing method for monitoring antimicrobial therapy in severe infections like endocarditis and osteomyelitis.
• It assesses a patient's serum activity against the causative pathogen, adapted from broth dilution techniques.
• Recent efforts focus on standardizing variables influencing SBT results.

Purpose of the Study:

• To evaluate the adequacy of current serum bactericidal titer (SBT) goals in clinical practice.
• To provide evidence-based recommendations for optimal SBT targets in treating serious bacterial infections.
• To highlight the need for standardized methods for future clinical trials.

Main Methods:

• The study reviews existing data and clinical recommendations for the serum bactericidal test (SBT).
• It analyzes the correlation between SBT results and treatment outcomes in patients with bacterial endocarditis and osteomyelitis.
• The methodology involves assessing the impact of different titer goals on therapeutic success and toxicity.

Main Results:

• A peak bactericidal titer of 1:8, commonly recommended for infective endocarditis, may be insufficient for some patients.
• Higher peak titers (1:64 or greater) in microdilution SBT are suggested for endocarditis if achievable without toxicity.
• Peak SBT titers of 1:8 or higher correlate with high cure rates in pediatric osteomyelitis, though adult data are limited.

Conclusions:

• Current SBT guidelines may require adjustment, particularly for infective endocarditis treatment.
• Achieving higher peak titers (e.g., 1:64+) should be considered in endocarditis therapy when feasible.
• Standardized SBT protocols are essential for conducting multicenter trials and establishing definitive recommendations.